论文部分内容阅读
目的:观察依达拉奉治疗急性脑出血的疗效和安全性。方法:将100例急性脑出血患者随机分为治疗组和对照组各50例。对照组给予常规治疗。治疗组在常规治疗基础上加用依达拉奉30mg静脉滴注,每天2次,14天为1疗程。观察治疗前和治疗4周后临床神经功能缺损评分,记录不良反应及并发症发生率。结果:治疗4周后神经功能缺损评分治疗组显效率明显高于对照组(P<0.05),并发症发生率明显低于对照组(P<0.05),2组均未见明显不良反应。结论:依达拉奉治疗急性脑出血安全有效。
Objective: To observe the efficacy and safety of edaravone in the treatment of acute cerebral hemorrhage. Methods: 100 cases of acute cerebral hemorrhage were randomly divided into treatment group and control group of 50 cases. The control group was given routine treatment. The treatment group was given edaravone 30mg intravenously on the basis of routine treatment twice a day for 14 days as a course of treatment. Observed before treatment and after 4 weeks of treatment of clinical neurological deficit score, record adverse reactions and the incidence of complications. Results: After 4 weeks of treatment, the neurological deficit score was significantly higher in the treatment group than in the control group (P <0.05), and the complication rate was significantly lower than that of the control group (P <0.05). No significant adverse reactions were found in the two groups. Conclusion: Edaravone is safe and effective in treating acute cerebral hemorrhage.